# Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations

> **NCT07906262** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07906262
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-10-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07906262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07906262, "Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07906262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
